此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Clinical Study to Evaluate JCXH-213 in the Treatment of Adults With Primary Immune Thrombocytopenia

2026年5月27日 更新者:Xiao Wang、The General Hospital of Western Theater Command

An Open-label, Single-arm, Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of JCXH-213 in the Treatment of Adults With Primary Immune Thrombocytopenia

This is an open-label, single-arm, dose-escalation study designed to evaluate the safety, tolerability, recommended subsequent dose, pharmacokinetic profile, and preliminary efficacy of JCXH-213 in adult patients with primary immune thrombocytopenia (ITP) who are refractory or relapsed after treatment with corticosteroids and second-line therapies.

The study consists of a screening period, treatment period, end-of-treatment visit, safety follow-up, and study withdrawal visit. Two dose groups are planned: 2 mg and 4 mg, with 2 patients to be enrolled in each dose group. During the treatment period, JCXH-213 at the assigned dose will be administered once every other day for a total of 7 doses. Assessments for safety and efficacy will be conducted according to the study schedule. After the last dose, patients will undergo an end-of-treatment visit and safety follow-up until the end of the study.

研究概览

地位

尚未招聘

干预/治疗

研究类型

介入性

注册 (估计的)

4

阶段

  • 阶段1

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria

  1. Voluntarily sign the informed consent form (ICF) and be expected to complete the follow-up visits and treatment required by the study protocol.
  2. Age ≥ 18 years and ≤ 65 years at screening, male or female.
  3. Clinical diagnosis of primary immune thrombocytopenia (ITP) for no less than 3 months, according to the American Society of Hematology 2011 Evidence-Based Practice Guideline (Neunert et al. 2011) or the International Consensus Report on the Investigation and Management of Primary Immune Thrombocytopenia (Provan et al. 2010), as applicable.

    Failure (ineffective, loss of maintenance of response, or relapse) of corticosteroid therapy and failure (ineffective, loss of maintenance of response, or relapse) or intolerance to at least one second-line ITP therapy.

  4. At least one second-line ITP therapy includes: rituximab and/or recombinant human thrombopoietin (rhTPO, e.g., TPO), thrombopoietin receptor agonists (TPO-RA, e.g., eltrombopag, hetrombopag, avatrombopag, romiplostim).

    Ineffectiveness is defined as platelet count < 30 × 10⁹/L after receiving the following treatments:

    Rituximab: 375 mg/m² once weekly for 4 doses; rhTPO: 300 U/kg/day for more than 14 days; Eltrombopag: 75 mg/day for more than 28 days; Hetrombopag: 7.5 mg/day for more than 28 days; Avatrombopag: 60 mg/day for more than 28 days; Romiplostim: up to a maximum weekly dose of 10 μg/kg for more than 28 days.

  5. Platelet count < 30 × 10⁹/L within 48 hours prior to the first dose of study drug (at least two consecutive platelet counts < 30 × 10⁹/L, at least 1 day apart, during screening and/or prior to first dose).
  6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.
  7. Patients receiving stable-dose maintenance therapy, including corticosteroids (not exceeding 0.5 mg/kg/day prednisone or equivalent) or thrombopoietin receptor agonists, may be enrolled, provided that the patient is on only one concomitant medication with stable dose and frequency, and the concomitant medication has been stable for at least 4 weeks prior to the first infusion of study drug.
  8. Adequate organ function, meeting the following laboratory criteria:

    Coagulation function:

    Activated partial thromboplastin time (APTT) ≤ 1.5 × upper limit of normal (ULN) Prothrombin time (PT) ≤ 1.5 × ULN

    Liver function:

    Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN Total bilirubin ≤ 1.5 × ULN, unless documented Gilbert's syndrome Patients with Gilbert-Meulengracht syndrome may be included if total bilirubin ≤ 3.0 × ULN and direct bilirubin ≤ 1.5 × ULN

    Renal function:

    Serum creatinine ≤ 1.5 × ULN, or creatinine clearance ≥ 60 mL/min (Cockcroft-Gault formula; see Appendix 1)

    Hematology (without blood transfusion, platelet transfusion, or growth factor use within 7 days prior to screening hematology assessment):

    Hemoglobin ≥ 80 g/L Absolute neutrophil count (ANC) ≥ 1.0 × 10⁹/L Absolute lymphocyte count (LY) ≥ 0.5 × 10⁹/L

    Cardiopulmonary function:

    Left ventricular ejection fraction (LVEF) ≥ 45% Oxygen saturation ≥ 91% without supplemental oxygen

  9. Female patients of childbearing potential must have a negative pregnancy test at screening. Any male or female patient of childbearing potential must agree to use effective contraceptive methods from the time of signing the ICF through at least 6 months after the last infusion of JCXH-213.

Female patients not of childbearing potential must meet at least one of the following criteria:

Have undergone hysterectomy, bilateral salpingectomy, or bilateral oophorectomy; Medically confirmed postmenopausal (at least 12 consecutive months of amenorrhea without pathological or physiological cause, with reproductive status assessed by hormone levels if necessary).

Exclusion Criteria

  1. Diagnosis of autoimmune hemolytic anemia, any secondary or hereditary thrombocytopenic disorders, including leukemia, lymphoma, multiple myeloma, aplastic anemia, myelodysplastic syndrome, Evans syndrome, common variable immunodeficiency, systemic lupus erythematosus, liver cirrhosis, antiphospholipid syndrome, pseudothrombocytopenia, or drug-induced thrombocytopenia (e.g., due to quinine, heparin, antibiotics, or antiepileptic drugs).
  2. History of any thromboembolic event or extensive/severe bleeding within 1 year prior to the first dose of study drug, such as hemoptysis, major upper gastrointestinal bleeding, intracranial hemorrhage, or presence of sepsis or other irregular bleeding.
  3. Receipt of anti-CD20 monoclonal antibody (e.g., rituximab) or other medicinal treatments (including cyclophosphamide and vindesine) within 3 months prior to the first dose of study drug.
  4. Receipt of the following medicinal treatments within 4 weeks prior to the first dose of study drug: azathioprine, danazol, dapsone, cyclosporine A, tacrolimus, or sirolimus.
  5. Use of anticoagulants or any antiplatelet agents (e.g., aspirin) within 3 weeks prior to the first dose of study drug.
  6. Receipt of emergency treatment for ITP (e.g., methylprednisolone, platelet transfusion, intravenous immunoglobulin, or TPO-RA) within 2 weeks prior to the first dose of study drug.
  7. Splenectomy within 6 months prior to the first dose of study drug.
  8. History of malignancy within 5 years prior to screening, with the exception of adequately treated cervical carcinoma in situ, basal cell or squamous cell carcinoma of the skin, localized prostate cancer after radical surgery, ductal carcinoma in situ after radical surgery, or thyroid cancer after radical surgery.
  9. Any unstable systemic disease, including but not limited to: uncontrolled active infection (excluding local infection); unstable angina pectoris; cerebrovascular accident or transient ischemic attack (within 6 months prior to screening); myocardial infarction or history of coronary angioplasty or stenting (within 6 months prior to screening); New York Heart Association (NYHA) Class III or IV cardiac insufficiency; refractory hypertension (defined as blood pressure not controlled after more than 1 month of treatment with ≥ 3 antihypertensive drugs [including diuretics] at reasonable and tolerable doses after lifestyle modification, or requiring ≥ 4 antihypertensive drugs to achieve blood pressure control); severe cardiac arrhythmia requiring medication; or significant hepatic, renal, or metabolic disease.
  10. Known or suspected history of immunosuppression, including invasive opportunistic infections such as histoplasmosis, coccidioidomycosis, coccidiosis, Pneumocystis jirovecii pneumonia, and aspergillosis, even if the infection has resolved; or unusually frequent, recurrent, or prolonged infections, as judged by the investigator.
  11. Positive peripheral blood test for hepatitis B virus (HBV) DNA; positive hepatitis C virus (HCV) antibody with positive peripheral blood HCV RNA; positive human immunodeficiency virus (HIV) antibody; positive cytomegalovirus (CMV) DNA; or positive Treponema pallidum test.
  12. Prior receipt of organ transplantation, or planned organ transplantation during the study period.
  13. Prior receipt of CAR-T therapy within 3 months.
  14. Active autoimmune or inflammatory neurological disorder (e.g., Guillain-Barré syndrome, amyotrophic lateral sclerosis).
  15. Clinically significant active cerebrovascular disease (e.g., cerebral edema, posterior reversible encephalopathy syndrome).
  16. Life expectancy of less than 3 months.
  17. Participation in another interventional clinical study and receipt of investigational drug within 1 month prior to enrollment (for marketed drugs, or investigational drugs with a known half-life, the shorter of 5 half-lives or 2 weeks applies).
  18. Receipt of live attenuated vaccine within 6 weeks prior to screening, or planned receipt of live attenuated vaccine during the study period.
  19. Contraindication or hypersensitivity to tocilizumab; contraindication or hypersensitivity to any component of the investigational product, JCXH-213.
  20. Pregnant or lactating women, or women planning to become pregnant or breastfeed from the time of signing the ICF through 6 months after the last infusion of JCXH-213; or male patients whose partner plans to become pregnant during this period.
  21. Any contraindication to any study procedure or other medical condition that, in the investigator's judgment and/or according to clinical standards, would place the patient at unacceptable risk.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Dose Level (2 mg,4 mg)
An mRNA-LNP based in vivo CAR therapy

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Safety and tolerability of JCXH-213
大体时间:The DLT observation period is 14 days after the first infusion of JCXH-213 (Day1-Day14).
Number of participants with adverse events (AEs), serious adverse events (SAEs), with abnormal laboratory tests results, abnormal electrocardiogram (ECG) readings, and abnormal vital signs
The DLT observation period is 14 days after the first infusion of JCXH-213 (Day1-Day14).

次要结果测量

结果测量
措施说明
大体时间
Platelet count over time
大体时间:Baseline to Month 4 (or longer at investigator's discretion)
Platelet count measured at Weeks 1, 2, 4, 8, and Months 3 and 4 after the first JCXH-213 infusion. If platelet count remains ≥ 30 × 10⁹/L at Month 4, extended follow-up may be performed at the investigator's discretion.
Baseline to Month 4 (or longer at investigator's discretion)
Time to platelet response
大体时间:From first infusion to Day 120
Time from first JCXH-213 infusion to first platelet count ≥ 30 × 10⁹/L with ≥ 2-fold increase from baseline, and time to first platelet count ≥ 50 × 10⁹/L.
From first infusion to Day 120
Cumulative weeks of platelet response
大体时间:From first infusion to Day 120
Cumulative weeks with platelet count ≥ 30 × 10⁹/L and ≥ 2-fold increase from baseline, and cumulative weeks with platelet count ≥ 50 × 10⁹/L, from first infusion to Day 120.
From first infusion to Day 120
Change in WHO bleeding score
大体时间:Baseline to Day 56
Change in World Health Organization (WHO) bleeding score from baseline to Day 56. The WHO bleeding score ranges from 0 to 4, with higher scores indicating worse bleeding outcomes.
Baseline to Day 56
Degree of disease control
大体时间:From first infusion to Day 120
Degree of disease control, defined as cumulative weeks with platelet count ≥ 50 × 10⁹/L over a specified period.
From first infusion to Day 120
Changes in platelet autoantibodies
大体时间:From first infusion to Day 120
Changes in platelet autoantibodies after JCXH-213 infusion, including: (1) quantitative detection of platelet surface-associated immunoglobulins (IgA, IgG, IgM); and (2) qualitative detection of platelet-specific and histocompatibility antibodies.
From first infusion to Day 120
Peripheral blood B-cell subset profiling
大体时间:From first infusion to Day 120
Peripheral blood B-cell subset distribution after JCXH-213 infusion, assessed by flow cytometry.
From first infusion to Day 120
Changes in peripheral blood JCXH-213 mRNA levels
大体时间:From within 1 hour before the first dose to 24 hours after the last dose (Day 14)
Changes in peripheral blood JCXH-213 mRNA levels after JCXH-213 infusion, assessed by quantitative PCR (qPCR)
From within 1 hour before the first dose to 24 hours after the last dose (Day 14)
Changes in peripheral blood CD19 CAR-positive cells
大体时间:From within 1 hour before the first dose to 24 hours after the last dose (up to Day 14)
Subset distribution and level changes of peripheral blood CD19 CAR-positive cells after JCXH-213 infusion, assessed by flow cytometry
From within 1 hour before the first dose to 24 hours after the last dose (up to Day 14)
Changes in peripheral blood cytokine levels
大体时间:From within 1 hour before the first dose to 24 hours after the last dose (up to Day 14)
Changes in peripheral blood cytokine levels, including interleukin-6 (IL-6), interferon-α (IFN-α), and interferon-γ (IFN-γ), after JCXH-213 infusion
From within 1 hour before the first dose to 24 hours after the last dose (up to Day 14)
Changes in anti-drug antibodies (ADA)
大体时间:From within 1 hour before the first dose to 24 hours after the last dose (up to Day 14)
Changes in peripheral blood anti-drug antibodies (ADA), including anti-CAR antibodies and anti-PEG antibodies, after JCXH-213 infusion
From within 1 hour before the first dose to 24 hours after the last dose (up to Day 14)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年6月18日

初级完成 (估计的)

2026年8月30日

研究完成 (估计的)

2027年6月30日

研究注册日期

首次提交

2026年5月21日

首先提交符合 QC 标准的

2026年5月27日

首次发布 (实际的)

2026年6月3日

研究记录更新

最后更新发布 (实际的)

2026年6月3日

上次提交的符合 QC 标准的更新

2026年5月27日

最后验证

2026年5月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅